Nasdaq

Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

MARLBOROUGH, Mass., Dec. 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ ...
Nasdaq

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints

MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ...
MedPage Today

Pulsed Field Ablation May Bridge Gender Gap in AF Ablation

The clinical benefits and safety of pulsed field ablation (PFA) for atrial fibrillation (Afib) appeared to span both sexes in real-world practice, according to a postapproval registry from Europe.
BioWorld

FDA greenlights Boston Sci’s Farapulse for persistent AF

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...
Medscape

FDA Okays Boston Scientific PFA System for Paroxysmal AF

Boston Scientific has received US Food and Drug Administration (FDA) approval for the Farapulse Pulsed Field Ablation (PFA) system for the isolation of pulmonary veins in the treatment of ...